(Q33597460)

28 July 2017

1 reference

title

Motor fluctuations in Parkinson's disease: pathophysiology and treatment (English)

1 reference

28 July 2017

1 reference

1 reference

C Colosimo

1

1 reference

28 July 2017

M De Michele

series ordinal

2

1 reference

28 July 2017

publication date

1 January 1999

1 reference

European Journal of Neurology

28 July 2017

published in

1 reference

28 July 2017

volume

6

1 reference

28 July 2017

issue

1

1 reference

28 July 2017

page(s)

1-21

1 reference

Practical aspects of the development of ex vivo and in vivo gene therapy for Parkinson's disease

28 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Pallidal stimulation for Parkinson's disease. Two targets?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Suppression of dyskinesias in advanced Parkinson's disease. II. Increasing daily clozapine doses suppress dyskinesias and improve parkinsonism symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

THERAPEUTIC EFFICACY OF APOMORPHINE COMBINED WITH AN EXTRACEREBRAL INHIBITOR OF DOPAMINE RECEPTORS IN PARKINSON'S DISEASE

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Gastric emptying in Parkinson's disease: patients with and without response fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Stereotactic ventral pallidotomy for Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Preclinical pharmacology of ropinirole (SK&F 101468-A) a novel dopamine D2 agonist.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged-Fischer-344 rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Controlled-release carbidopa/levodopa (CR4-Sinemet) in Parkinson's disease patients with and without motor fluctuations.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Entacapone in combination with standard or controlled-release levodopa/carbidopa: a clinical and pharmacokinetic study in patients with Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Intranasal apomorphine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Neuropathological evidence of graft survival and striatal reinnervation after the transplantation of fetal mesencephalic tissue in a patient with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Stimulation of subthalamic nucleus alleviates tremor in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Subthalamic nucleus or internal pallidal stimulation in young onset Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Posteroventral medial pallidotomy in advanced Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Biology of glial cell line-derived neurotrophic factor (GDNF): implications for the use of GDNF to treat Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Pergolide in the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Role of selegiline in combination therapy of Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Effect of peripheral catechol-O-methyltransferase inhibition on the pharmacokinetics and pharmacodynamics of levodopa in parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

A radical hypothesis for neurodegeneration

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

A study of medial pallidotomy for Parkinson's disease: clinical outcome, MRI location and complications.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Cognitive sequelae of unilateral posteroventral pallidotomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

The anti-parkinsonian drug amantadine inhibits the N-methyl-D-aspartic acid-evoked release of acetylcholine from rat neostriatum in a non-competitive way

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Unilateral pallidotomy for Parkinson's disease: comparison of outcome in younger versus elderly patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Intranasal apomorphine in parkinsonian on-off fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Treatment of Parkinsonism With Levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

"On-off" phenomenon with levodopa therapy in Parkinsonism. Clinical and pharmacologic correlations and the effect of intramuscular pyridoxine

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Peripheral pharmacokinetics of levodopa in untreated, stable, and fluctuating parkinsonian patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Time interval between repeated injections conditions the duration of motor improvement to apomorphine in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Nonmotor fluctuations in patients with Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Intermittent subcutaneous apomorphine injection treatment for parkinsonian motor oscillations

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Does an inhibitory action of levodopa contribute to motor fluctuations?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Effect of long-term therapy on the pharmacodynamics of levodopa. Relation to on-off phenomenon

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Effect of brief levodopa holidays on the short-duration response to levodopa: evidence for tolerance to the antiparkinsonian effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Long-duration response to levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Influence of dietary protein on motor fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Oral pulse levodopa therapy in mild Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Control of on/off phenomenon by continuous intravenous infusion of levodopa

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Tolcapone improves motor function in parkinsonian patients with the "wearing-off" phenomenon: a double-blind, placebo-controlled, multicenter trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

The spectrum of levodopa-related fluctuations in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Efficacy of pramipexole, a novel dopamine agonist, as monotherapy in mild to moderate Parkinson's disease. The Pramipexole Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Levodopa peak response time reflects severity of dopamine neuron loss in Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

Effects of supra-threshold levodopa doses on dyskinesias in advanced Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1468-1331.1999.610001.X

10.1046/J.1468-1331.1999.610001.X

21 January 2018

Identifiers

DOI

1 reference

28 July 2017

1 reference